Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : Vodobatinib
CAS No.: 1388803-90-4
Catalog No.: PC-38379Not For Human Use, Lab Use Only.
Vodobatinib (K0706) is a potent, selective inhibitor of BCR-ABL1 with IC50 of 7 nM (wt BCR-ABL1), exhibits activity against most clinically important BCR-ABL1 point mutants (M244V, IC50=22 nM).
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 10 mg | $128 | In stock | |
| 25 mg | $218 | In stock | |
| 50 mg | $358 | In stock | |
| 100 mg | $558 | In stock | |
| 250 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Vodobatinib (K0706) is a potent, selective inhibitor of BCR-ABL1 with IC50 of 7 nM (wt BCR-ABL1), exhibits activity against most clinically important BCR-ABL1 point mutants (M244V, IC50=22 nM).
The only BCR-ABL1 point mutants with IC50 above 100 nM are: BCR-ABL1L248R (IC50: 167 nM), BCR-ABL1Y253H (IC50: 154 nM), BCR-ABL1E255V (IC50: 165 nM) and BCR-ABL1T315I (IC50: 1967 nM).
Vodobatinib (K0706) demonstrated direct, potent inhibition of BCR-ABL1 tyrosine autophosphorylation as well as inhibition of BCR-ABL1L248R, BCR-ABL1Y253H and BCR-ABL1E255V at high concentrations in a panel of cell lines expressing TKI resistant mutants of BCR-ABL1.
Vodobatinib (K0706) does not inhibit mutant BCR-ABL1T315I.
Vodobatinib (K0706) exhibited pre-clinical activity in Philadelphia chromosome-positive leukemia.
| M.Wt | 453.926 | |
| Formula | C27H20ClN3O2 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
2-chloro-6-methyl-N'-(4-methyl-3-(quinolin-3-ylethynyl)benzoyl)benzohydrazide |
|
1. Antelope O, et al. Exp Hematol. 2019 Sep;77:36-40.e2.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
